Skip to main content
Fig. 8 | Acta Neuropathologica Communications

Fig. 8

From: Systemic delivery of a specific antibody targeting the pathological N-terminal truncated tau peptide reduces retinal degeneration in a mouse model of Alzheimer’s Disease

Fig. 8

12A12mAb as novel tau-directed immunotherapeutic tool for the clinical treatment of retinal degeneration associated with AD. a A graphical illustration showing the parallel neuroprotective effects of 12A12mAb on both aging brain [136] and eye. b Schematic representation showing the 12A12mAb-mediated neutralization of the AD-relevant N-truncated tau fragment residing in ocular structures and its beneficial actions on alterations associated with visual impairment in Tg2576 animal model

Back to article page